Ferring Pharmaceuticals Ltd.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$16.6M
Doctors Paid
37,533
Transactions
173,149
2024 Total
$2.0M
Payment Breakdown by Category
Consulting$5.0M (30.0%)
Food & Beverage$3.4M (20.4%)
Research$3.4M (20.2%)
Travel$1.2M (7.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5.0M | 1,061 | 30.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.5M | 1,909 | 21.0% |
| Food and Beverage | $3.4M | 162,916 | 20.4% |
| Unspecified | $3.4M | 133 | 20.2% |
| Travel and Lodging | $1.2M | 4,813 | 7.5% |
| Education | $77,481 | 2,290 | 0.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $30,835 | 14 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $18,000 | 6 | 0.1% |
| Grant | $5,400 | 2 | 0.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,500 | 5 | 0.0% |
Payments by Type
General
$13.2M
173,016 transactions
Research
$3.4M
133 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase II Study of Docetaxel Before Medical Castration with Degarelix in Patients with Newly Diagnosed Metastatic Prostatic Adenocarcinoma | $1.0M | 0 | 20 |
| Phase III Randomized Trial Comparing Short Course Androgen Deprivation Therapy and Ultra-Hypofractionated SBRT Versus SBRT Alone For Intermediate Prostate Cancer | $371,746 | 0 | 6 |
| Administration of FSH and Low Dose hCG for Oocyte Maturity While Decreasing hCG Exposure in IVF Cycles | $259,174 | 0 | 6 |
| A Prospective Pilot Study to Evaluate Efficacy and Safety of Euflexxa for the Treatment of Osteoarthritis | $235,856 | 0 | 6 |
| Vaginal Compared to Intramuscular Progesterone for Frozen Embryo Transfer | $216,424 | 0 | 3 |
| Combined Use of the Controlled Release Dinoprostone Insert and Foley Catheter Compared to the Foley Catheter Alone for Cervical Ripening and Labor Induction in Term Women A Randomized Controlled Trial | $116,717 | 0 | 5 |
| Aneuploidy Rates in Advanced Maternal Age Patients Supplemented With Coenzyme Q10 CoQ10 Versus Those That Are Not a Pilot Study | $112,171 | 0 | 2 |
| A Trial of Cervadil dinoprostone PGE 2 insert for Outpatient Preinduction Cervical Ripening in Women at 39.0 to 41.6 weeks gestation | $103,427 | 0 | 3 |
| Clenpiq Low Residue Diet Study | $96,427 | 0 | 7 |
| A Pilot Study of Neoadjuvant Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer | $78,669 | 0 | 5 |
| Retrospective Study to Evaluate PatientsClinical Factors related to Positive Response from HA Injections | $78,030 | 0 | 2 |
| Randomized Phase 1b/2 Study of Nivolumab or Nivolumab Plus BMS-986253 in Combination with Degarelix in Men with Hormone-Sensitive Prostate Cancer | $66,688 | 0 | 21 |
| Randomized Comparison of the Impact of Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid versus Polyethylene Glycol Bowel Preparation on Inpatient Colonoscopy Quality Parameters | $64,878 | 0 | 4 |
| The Impact of the Timing of Trigger on IVF Success | $52,773 | 0 | 2 |
| Pre-Implantation Screening and INvestigation on the Cryopreservation of Embryos PrISICE | $52,773 | 0 | 2 |
| Randomized Phase 1b2 Study of Nivolumab or Nivolumab Plus BMS-986253 in Combination With Intermittent Androgen Deprivation Therapy in Men With Hormone-Sensitive Prostate Cancer | $52,562 | 0 | 7 |
| Clinical Outcomes after Formal Cervidil Training COACT | $50,814 | 0 | 1 |
| The Effects and Tolerability of a Prescribed Low Residue Diet the Day Before Colonoscopy on the Cleanliness of the Colon vs. the Traditional Clear Liquid, Day Before Diet With the Use of the Clenpiq Bowel Purgative | $49,665 | 0 | 3 |
| The Effects and Tolerability of a Prescribed Low Residue Diet the Day Before Colonoscopy on the Cleanliness of the Colon vs. the Traditional Clear Liquid, Day Before Diet with the use of the Clenpiq Bowel Purgative | $40,000 | 1 | 1 |
| The Impact of the Timing of Trigger on IVF Success Randomized Control Trial | $33,057 | 0 | 3 |
| Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer MAGIC-8 | $29,895 | 0 | 1 |
| A Prospective, Randomized, Controlled Clinical Trial Evaluating the Superiority of Preimplantation Genetic Screening (PGS) and Deferred Transfer of Cryopreserved Embryos Over "Freeze-Only" Deferred Transfer Without PGS or Immediate Embryo Transfer During a "Fresh" In Vitro Fertilization Cycle | $26,387 | 0 | 3 |
| Evaluation of Follicular Fluid and Granulosa Cells from IVF Patients for Markers of Reproductive Aging | $25,465 | 0 | 3 |
| Nivolumab and BMS-986253 combined with Degarelix for Hormone-Sensitive Prostate Cancer | $19,538 | 0 | 3 |
| AMH and Doing Regimens for Initial IVF Stimulation Protocols | $18,818 | 0 | 1 |
| Degarelix Acetate Prior to Radiation Therapy | $16,259 | 0 | 1 |
| A Phase II Study of Docetaxel Before Medical Castration With Degarelix in Patients With Newly Diagnosed Metastatic Prostatic Adenocarcinoma. | $14,283 | 0 | 3 |
| Gonadotropin LHFSH-releasing hormone GnRH Antagonists Evaluation of Beneficial Effects for Alzheimers Disease | $11,234 | 0 | 1 |
| Association of fertility preservation health insurance benefit mandates with utilization of ART banking and philanthropic fertility drug programs among females newly diagnosed with cancer. | $10,080 | 0 | 1 |
| A Randomized, Pragmatic, Effectiveness Trial Evaluating Intra-articular Hyaluronan for the Symptomatic Treatment of Chronic Patellofemoral Pain Syndrome | $9,382 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 6
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Daniel Christie, Md, MD | Reproductive Endocrinology | Margate, FL | $18,183 | $0 |
| Dr. Jason Bromer, M.d, M.D | Reproductive Endocrinology | Frederick, MD | $17,854 | $0 |
| Bill Mc Carberg, Md, MD | Family Medicine | San Diego, CA | $17,796 | $0 |
| Dr. David Frankfurter, Md, MD | Reproductive Endocrinology | New Haven, CT | $17,717 | $0 |
| Jason Fond, Md, MD | Orthopaedic Surgery | Nanuet, NY | $17,674 | $0 |
| Jason Sniffen, Do, DO | Infectious Disease | Altamonte Springs, FL | $17,073 | $0 |
| Dr. Thomas Keane, Md, MD | Urology | Charleston, SC | $16,969 | $0 |
| Charles Drake, M.d, M.D | Hematology & Oncology | New York, NY | $16,961 | $0 |
| Dr. Latasha Craig, M.d, M.D | Reproductive Endocrinology | Oklahoma City, OK | $16,933 | $0 |
| Erin Duhaime, Pa-C, PA-C | Medical | Dallas, TX | $16,743 | $0 |
| Dr. David Sable, Md, MD | Reproductive Endocrinology | New York, NY | $16,724 | $0 |
| Dr. Kim Thornton, Md, MD | Reproductive Endocrinology | Waltham, MA | $16,656 | $0 |
| Dr. Robert Olson, M.d, M.D | Obstetrics & Gynecology | Spokane, WA | $16,568 | $0 |
| Dr. Leonard Gomella, M.d, M.D | Urology | Philadelphia, PA | $16,287 | $0 |
| Dr. Gary Zeluff, M.d, M.D | Orthopaedic Surgery | Richfield, UT | $16,110 | $0 |
| Kenneth Lecroy, M.d, M.D | Family Medicine | Colleyville, TX | $16,005 | $0 |
| Jeffrey Frankel, Md, MD | Specialist | Burien, WA | $15,960 | $0 |
| Stephen Saddemi, M.d, M.D | Sports Medicine | Toledo, OH | $15,929 | $0 |
| Lawrence Engmann, Md, MD | Reproductive Endocrinology | Hartford, CT | $15,925 | $0 |
| Asim Khan, Md, MD | Rheumatology | Maple Grove, MN | $15,857 | $0 |
| Dr. Michael Dorsi, Md, MD | Neurological Surgery | Thousand Oaks, CA | $15,857 | $0 |
| Dr. Pamela Kushner, M.d, M.D | Family Medicine | Los Angeles, CA | $15,737 | $0 |
| Dr. Rafat Abbasi, M.d, M.D | Specialist | Washington, DC | $15,681 | $0 |
| Lauren Nervi | Family | Basking Ridge, NJ | $15,612 | $0 |
| Dr. Javine Mclaughlin, Md, Facog, MD, FACOG | Obstetrics & Gynecology | Parsons, KS | $15,557 | $0 |
Ad
Top Products
- MENOPUR $3.1M
- EUFLEXXA $2.0M
Associated Products (12)
- REBYOTA $3.9M
- FIRMAGON $3.1M
- EUFLEXXA $2.0M
- ADSTILADRIN $1.6M
- CLENPIQ $1.1M
- CERVIDIL $563,608
- ENDOMETRIN $476,911
- FIRMAGON 240 $394,398
- INVOCELL $257,492
- CIMZIA $243,508
- NOVAREL $56,006
- FIRMAGON 80 $11,234
Payment Categories
- Food & Beverage $3.4M
- Consulting $5.0M
- Travel & Lodging $1.2M
- Research $3.4M
About Ferring Pharmaceuticals Ltd.
Ferring Pharmaceuticals Ltd. has made $16.6M in payments to 37,533 healthcare providers, recorded across 173,149 transactions in the CMS Open Payments database. In 2024, the company paid $2.0M. The top product by payment volume is MENOPUR ($3.1M).
Payments were distributed across 192 medical specialties. The top specialty by payment amount is Reproductive Endocrinology ($2.7M to 930 doctors).
Payment categories include: Food & Beverage ($3.4M), Consulting ($5.0M), Research ($3.4M), Travel & Lodging ($1.2M).
Ferring Pharmaceuticals Ltd. is associated with 12 products in the CMS Open Payments database, including REBYOTA, FIRMAGON, and EUFLEXXA.